Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Schizophrenia

Free Subscription Articles published in Mol Psychiatry Retrieve available abstracts of 202 articles: HTML format

Single Articles

May 2026
1. CAO L, Maleki Balajoo S, Gao Y, Li H, et al
   Common alterations of whole and subregion-specific amygdala intrinsic functional connectivity across psychiatric disorders: a meta-analysis.
   Mol Psychiatry. 2026;31:2916-2926.
   PubMed     Abstract available
   
   
   April 2026
2. NUSSBAUMER M, Guest PC, Schiltz K, Dudeck L, et al
   Multimodal microglial and kynurenine pathway alterations across the affective-psychosis spectrum: a systematic review of patterns, heterogeneity, and dimensional implications.
   Mol Psychiatry. 2026 Apr 21. doi: 10.1038/s41380-026-03614.
   PubMed     Abstract available
   
   
   
3. CUI L, Kurganov E, Hawes D, Hornauer P, et al
   Loss of schizophrenia risk gene XPO7 disrupts neuronal excitability and network regularity via altered Na(+) channel dynamics in human neurons.
   Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03587.
   PubMed     Abstract available
   
   
   
4. CHENG M, Yin Y, Engchuan W, Heung T, et al
   Genome-wide tandem repeat expansions modify schizophrenia risk in the presence of a 22q11.2 deletion.
   Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03574.
   PubMed     Abstract available
   
   
   
5. MCKENNA F, Vinke LN, Williams M, Gaw M, et al
   Postpartum psychosis is associated with elevated neuromelanin-MRI signal in the midbrain.
   Mol Psychiatry. 2026 Apr 15. doi: 10.1038/s41380-026-03476.
   PubMed     Abstract available
   
   
   
6. FENNER E, Holmans P, O'Donovan MC, Owen MJ, et al
   Analysis of rare coding variants in schizophrenia-associated genes and generalised cognition in the UK Biobank.
   Mol Psychiatry. 2026 Apr 10. doi: 10.1038/s41380-026-03601.
   PubMed     Abstract available
   
   
   
7. YANG X, Agartz I, Andreassen O, Bachman P, et al
   Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.
   Mol Psychiatry. 2026 Apr 4. doi: 10.1038/s41380-026-03586.
   PubMed     Abstract available
   
   
   
8. DAI SS, Dang X, Gong D, Li D, et al
   Molecular regulatory mechanisms of schizophrenia-associated functional non-coding variants.
   Mol Psychiatry. 2026 Apr 2. doi: 10.1038/s41380-026-03566.
   PubMed     Abstract available
   
   
   
9. SEUFFERT S, Mulfarth RR, Teutenberg L, Thomas-Odenthal F, et al
   Linking speech patterns to brain structure in affective and psychotic disorders: an integrative natural language processing approach.
   Mol Psychiatry. 2026;31:2057-2068.
   PubMed     Abstract available
   
   
   
10. LI Q, Liu J, Pearlson GD, Chen J, et al
    Spatiotemporal complexity in the psychotic brain.
    Mol Psychiatry. 2026;31:2014-2028.
    PubMed     Abstract available
    
    
    
11. TANAKA R, Liao J, Liu Y, Zhu W, et al
    Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia.
    Mol Psychiatry. 2026 Apr 1. doi: 10.1038/s41380-026-03567.
    PubMed     Abstract available
    
    
    March 2026
12. ETYEMEZ S, Sivananthan R, Faria AV, Iasevoli F, et al
    Brain structural abnormalities in treatment-resistant schizophrenia.
    Mol Psychiatry. 2026 Mar 28. doi: 10.1038/s41380-026-03558.
    PubMed     Abstract available
    
    
    
13. ZHANG S, Chen Y, Zhang L, Yang X, et al
    Global lifetime prevalence of schizophrenia: A systematic review and meta-analysis.
    Mol Psychiatry. 2026 Mar 23. doi: 10.1038/s41380-026-03533.
    PubMed     Abstract available
    
    
    
14. DAMIANI S, Stefanelli R, Fortea L, D'Imperio A, et al
    Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials.
    Mol Psychiatry. 2026 Mar 23. doi: 10.1038/s41380-026-03543.
    PubMed     Abstract available
    
    
    
15. OLIVER LD, Yu JC, Hawco C, Calarco N, et al
    Multivariate relationships between social cognitive performance and functional connectivity during task and rest across schizophrenia spectrum disorders and healthy controls.
    Mol Psychiatry. 2026 Mar 12. doi: 10.1038/s41380-026-03504.
    PubMed     Abstract available
    
    
    
16. LAABOUB N, Vandenberghe F, Ansermot N, Piras M, et al
    Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses.
    Mol Psychiatry. 2026;31:1420-1430.
    PubMed     Abstract available
    
    
    February 2026
17. LI X, Zeng J, Liu N, Tang B, et al
    Functional brain abnormalities of cognitive impairments in schizophrenia indicating higher integration of working memory than other domains.
    Mol Psychiatry. 2026 Feb 27. doi: 10.1038/s41380-026-03518.
    PubMed     Abstract available
    
    
    
18. KINJO M, Tamura S, Sugiyama S, van Weert E, et al
    A systematic review and meta-analysis of the auditory steady-state response in schizophrenia, bipolar disorder, and autism spectrum disorder.
    Mol Psychiatry. 2026 Feb 3. doi: 10.1038/s41380-026-03452.
    PubMed     Abstract available
    
    
    
19. DE SIMONE G, De Prisco M, Oliva V, Vellucci L, et al
    Molecular and topographic mapping of antipsychotic effects: a meta-analysis of postsynaptic density proteins in animal models with translational implications.
    Mol Psychiatry. 2026;31:1142-1155.
    PubMed     Abstract available
    
    
    January 2026
20. WATSON CJ, Zvrskovec J, Merola GP, Gilchrist L, et al
    Splitting schizophrenia: divergent cognitive and educational outcomes revealed by genomic structural equation modelling.
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03444.
    PubMed     Abstract available
    
    
    
21. LLORCA-BOFI V, Parellada E, Moren C, Sellgren CM, et al
    Neuroinflammation: an unfortunate term to describe schizophrenia.
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03450.
    PubMed     Abstract available
    
    
    
22. MEMETOGLU O, Goyal MS, Chouinard VA, Du F, et al
    Aerobic glycolysis in Schizophrenia: Developmental rescue or energetic breakdown?
    Mol Psychiatry. 2026 Jan 31. doi: 10.1038/s41380-026-03460.
    PubMed     Abstract available
    
    
    
23. UCHIYAMA S, Saito T, Liu X, Ishikawa Y, et al
    Associations between mosaic loss and schizophrenia or bipolar disorder of young age.
    Mol Psychiatry. 2026 Jan 15. doi: 10.1038/s41380-025-03397.
    PubMed     Abstract available
    
    
    
24. LEMKE JR, Eoli A, Krey I, Popp B, et al
    Correction: GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.
    Mol Psychiatry. 2026 Jan 7. doi: 10.1038/s41380-025-03442.
    PubMed    
    
    
    December 2025
25. WANG L, Zhang J, Geng L, Chen B, et al
    Associative memory neurons are recruited in PFC-centered circuits to encode schizophrenia-like behavior by dopaminergic receptor-II.
    Mol Psychiatry. 2025 Dec 15. doi: 10.1038/s41380-025-03388.
    PubMed     Abstract available
    
    
    
26. DANG X, Gong D, Dai SS, Teng Z, et al
    Genetic and functional insights into long noncoding RNAs in schizophrenia.
    Mol Psychiatry. 2025 Dec 14. doi: 10.1038/s41380-025-03421.
    PubMed     Abstract available
    
    
    
27. CHU RS, Fung VS, Lei JH, Wong GH, et al
    Rate and predictors of remission and recovery in first-episode psychosis: A 12-year follow-up of randomized-controlled trial on early intervention.
    Mol Psychiatry. 2025 Dec 12. doi: 10.1038/s41380-025-03409.
    PubMed     Abstract available
    
    
    
28. HARTMANN SM, Pizarro Garcia P, Heider J, Vogel S, et al
    A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype.
    Mol Psychiatry. 2025 Dec 12. doi: 10.1038/s41380-025-03384.
    PubMed     Abstract available
    
    
    
29. LAMSMA J, Raine A, Kia SM, Cahn W, et al
    Structural brain abnormalities and aggression in schizophrenia: mega-analysis of data from 2095 patients and 2861 healthy controls via the ENIGMA consortium.
    Mol Psychiatry. 2025 Dec 3. doi: 10.1038/s41380-025-03365.
    PubMed     Abstract available
    
    
    November 2025
30. POWELL SK, Liao W, Ghorbani S, Rigat R, et al
    3D genetic architecture of schizophrenia risk across three neuronal subtypes.
    Mol Psychiatry. 2025 Nov 28. doi: 10.1038/s41380-025-03352.
    PubMed     Abstract available
    
    
    
31. ZHANG T, Xu L, Wei Y, Cui H, et al
    Cognitive trajectories of psychosis risk: temporal patterns and association with progression.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03371.
    PubMed     Abstract available
    
    
    
32. YE L, Ni C, Chen R, Che S, et al
    Mendelian randomization facilitates identification of schizophrenia risk enhancer RNAs.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03358.
    PubMed     Abstract available
    
    
    
33. MARTIN ECHAVE M, Schnack HG, Diaz-Caneja CM, Pina-Camacho L, et al
    Individualized cortical thickness asymmetry in autism spectrum disorder and schizophrenia.
    Mol Psychiatry. 2025 Nov 23. doi: 10.1038/s41380-025-03359.
    PubMed     Abstract available
    
    
    
34. DEAKIN B, Liddle E, Rathnaiah M, Gregory CC, et al
    Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences.
    Mol Psychiatry. 2025 Nov 19. doi: 10.1038/s41380-025-03337.
    PubMed     Abstract available
    
    
    
35. VELEZ-PEREZ E, Demirlek C, Zeng V, Silverstein S, et al
    Retinal cytoarchitectural alterations across the psychosis spectrum and their correlates with cognition: a UK biobank nested case-control study.
    Mol Psychiatry. 2025 Nov 15. doi: 10.1038/s41380-025-03343.
    PubMed     Abstract available
    
    
    
36. CRESPI BJ
    Evaluating evidence for convergence between autism and schizophrenia.
    Mol Psychiatry. 2025 Nov 1. doi: 10.1038/s41380-025-03334.
    PubMed    
    
    
    October 2025
37. BATALLA A, Somers M, Meer PV
    Psychedelics, psychosis, and the elusive notion of safety.
    Mol Psychiatry. 2025 Oct 24. doi: 10.1038/s41380-025-03315.
    PubMed    
    
    
    
38. LIU S, Agartz I, Allen P, Amminger GP, et al
    Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.
    Mol Psychiatry. 2025 Oct 22. doi: 10.1038/s41380-025-03304.
    PubMed     Abstract available
    
    
    
39. HU Y, Wang Z, Fang J, Zhang S, et al
    Selective magnetic stimulation downregulates the GABA(A) receptor epsilon subunit in the left prelimbic cortex to alleviate schizophrenia-like behaviors in mice.
    Mol Psychiatry. 2025 Oct 14. doi: 10.1038/s41380-025-03267.
    PubMed     Abstract available
    
    
    
40. LEMKE JR, Eoli A, Krey I, Popp B, et al
    GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.
    Mol Psychiatry. 2025 Oct 14. doi: 10.1038/s41380-025-03279.
    PubMed     Abstract available
    
    
    
41. WALTHER S, Maderthaner L, Chapellier V, von Kanel S, et al
    Gesture deficits in psychosis and the combination of group psychotherapy and transcranial magnetic stimulation: A randomized clinical trial.
    Mol Psychiatry. 2025 Oct 8. doi: 10.1038/s41380-025-03303.
    PubMed     Abstract available
    
    
    
42. MARTINEZ-SADURNI L, Barrera-Conde M, Robledo P, Veza-Estevez E, et al
    Differential effect of cannabis use and antipsychotic medication on extracellular free-water in the brain of individuals with early psychosis and controls.
    Mol Psychiatry. 2025 Oct 7. doi: 10.1038/s41380-025-03287.
    PubMed     Abstract available
    
    
    
43. CARR R, Cannon A, Finelli V, Bukala B, et al
    Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis.
    Mol Psychiatry. 2025 Oct 3. doi: 10.1038/s41380-025-03255.
    PubMed     Abstract available
    
    
    
44. OHTANI H, Ichikawa R, Mori K, Kato T, et al
    Single-molecule DNA analysis implicates brain mitochondria pathology in bipolar disorder.
    Mol Psychiatry. 2025;30:4764-4775.
    PubMed     Abstract available
    
    
    
45. DARDANI C, Robinson JW, Jones HJ, Rai D, et al
    Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions.
    Mol Psychiatry. 2025;30:4487-4496.
    PubMed     Abstract available
    
    
    September 2025
46. LU ZA, Ploner A, Birgegard A, Landen M, et al
    Leveraging transdiagnostic genetic liability to psychiatric disorders to dissect clinical outcomes of anorexia nervosa.
    Mol Psychiatry. 2025 Sep 23. doi: 10.1038/s41380-025-03264.
    PubMed     Abstract available
    
    
    
47. SINANAJ L, Pallis K, Dehkordi AF, Huguelet P, et al
    Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.
    Mol Psychiatry. 2025 Sep 22. doi: 10.1038/s41380-025-03238.
    PubMed     Abstract available
    
    
    
48. SU X, Zhang H, Hong Y, Yang Q, et al
    Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons.
    Mol Psychiatry. 2025 Sep 17. doi: 10.1038/s41380-025-03246.
    PubMed     Abstract available
    
    
    
49. BOJESEN KB, Lemvigh CK, Sigvard AK, Vestergaard MB, et al
    Cerebral glutamate levels over two years in initially antipsychotic-naive first-episode patients with psychosis are related to clinical symptoms and cognition.
    Mol Psychiatry. 2025 Sep 15. doi: 10.1038/s41380-025-03234.
    PubMed     Abstract available
    
    
    
50. BOJESEN KB, Ambrosen KS, Sigvard AK, Nielsen MO, et al
    Interrelations between dopaminergic-, gabaergic- and glutamatergic neurotransmitters in antipsychotic-naive psychosis patients and the association to initial treatment response.
    Mol Psychiatry. 2025 Sep 12. doi: 10.1038/s41380-025-03229.
    PubMed     Abstract available
    
    
    
51. LUKOW PB, Schubert JJ, Severino M, Knight SR, et al
    GABA(A) receptor availability in clinical high-risk and first-episode psychosis: a [(11)C]Ro15-4513 positron emission tomography study.
    Mol Psychiatry. 2025 Sep 6. doi: 10.1038/s41380-025-03204.
    PubMed     Abstract available
    
    
    
52. VANO LJ, McCutcheon RA, Sedlacik J, Rutigliano G, et al
    The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study.
    Mol Psychiatry. 2025 Sep 5. doi: 10.1038/s41380-025-03195.
    PubMed     Abstract available
    
    
    
53. AHIRWAR LK, Blackburn SL, McBride DW, T PK, et al
    Reviewing vascular influences on neuronal migration, cortical development, and neurodevelopmental disorders: focus on autism, ADHD and schizophrenia.
    Mol Psychiatry. 2025 Sep 2. doi: 10.1038/s41380-025-03200.
    PubMed     Abstract available
    
    
    
54. LU Z, Guo J, Sun J, Sun Y, et al
    The event-related potential components across psychiatric disorders: a systematic review and network meta-analysis.
    Mol Psychiatry. 2025;30:4422-4431.
    PubMed     Abstract available
    
    
    
55. SOLOMON P, Kaurani L, Budde M, Guine JB, et al
    Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders.
    Mol Psychiatry. 2025;30:4364-4383.
    PubMed     Abstract available
    
    
    
56. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Exploring the implications of case selection methods for psychiatric molecular genetic studies.
    Mol Psychiatry. 2025;30:4334-4342.
    PubMed     Abstract available
    
    
    
57. STEIN F, Gudjons AM, Brosch K, Keunecke LM, et al
    Transdiagnostic types of formal thought disorder and their association with gray matter brain structure: a model-based cluster analytic approach.
    Mol Psychiatry. 2025;30:4286-4295.
    PubMed     Abstract available
    
    
    
58. HOLTER KM, Klausner MG, Hite MH, Moriarty CT, et al
    17beta-estradiol status alters NMDAR function and antipsychotic-like activity in female rats.
    Mol Psychiatry. 2025;30:4161-4175.
    PubMed     Abstract available
    
    
    August 2025
59. WOODS RM, Potter HG, Kowash HM, McEwan F, et al
    Developmental modulation of schizophrenia risk gene methylation in offspring exhibiting cognitive deficits following maternal immune activation.
    Mol Psychiatry. 2025 Aug 29. doi: 10.1038/s41380-025-03147.
    PubMed     Abstract available
    
    
    
60. FAN YS, Xu Y, Hettwer MD, Yang P, et al
    Neurodevelopmentally rooted epicenters in schizophrenia: sensorimotor-association spatial axis of cortical thickness alterations.
    Mol Psychiatry. 2025 Aug 28. doi: 10.1038/s41380-025-03193.
    PubMed     Abstract available
    
    
    
61. UNZUETA-LARRINAGA P, Cuesta-Vega E, Barrena-Barbadillo R, Olabarrieta E, et al
    Extracellular matrix dysfunction and synaptic alterations in schizophrenia.
    Mol Psychiatry. 2025 Aug 27. doi: 10.1038/s41380-025-03154.
    PubMed     Abstract available
    
    
    
62. CUI Y, Sun J, Zhang B, Guo T, et al
    Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.
    Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03132.
    PubMed     Abstract available
    
    
    
63. WAKUDA T, Yokokura M, Magata Y, Suzuki C, et al
    alpha7 nicotinic acetylcholine receptor, activated glia, and cognitive impairment in schizophrenia: a dual-tracer PET study.
    Mol Psychiatry. 2025 Aug 19. doi: 10.1038/s41380-025-03162.
    PubMed     Abstract available
    
    
    
64. VAZIRI N, Shutt TE, Karim W, Raedler TJ, et al
    Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.
    Mol Psychiatry. 2025;30:3491-3501.
    PubMed     Abstract available
    
    
    July 2025
65. SALAMONE PC, Enmalm A, Kaldewaij R, Aman M, et al
    Altered processing of self-produced sensations in psychosis at cortical and spinal levels.
    Mol Psychiatry. 2025 Jul 25. doi: 10.1038/s41380-025-03130.
    PubMed     Abstract available
    
    
    
66. GARCIA-RIZO C, Bitanihirwe BKY
    Epiphenomena in psychosis: how perinatal stressful events shape long-term outcomes.
    Mol Psychiatry. 2025 Jul 11. doi: 10.1038/s41380-025-03096.
    PubMed     Abstract available
    
    
    
67. LI H, Zhao Z, Jiang S, Wu H, et al
    Brain circuits that regulate social behavior.
    Mol Psychiatry. 2025;30:3240-3256.
    PubMed     Abstract available
    
    
    
68. HAGENBEEK FA, Pool R, Van Asselt AJ, Ehli EA, et al
    Intergenerational transmission of complex traits and the offspring methylome.
    Mol Psychiatry. 2025;30:3338-3347.
    PubMed     Abstract available
    
    
    
69. HERRERO F, Heeb C, Meier M, Lin HY, et al
    Recapitulation and reversal of neuropsychiatric phenotypes in a mouse model of human endogenous retrovirus type W expression.
    Mol Psychiatry. 2025;30:3325-3337.
    PubMed     Abstract available
    
    
    
70. KIM H, Jung JH, Han K, Jeon HJ, et al
    Risk of suicide and all-cause death in patients with mental disorders: a nationwide cohort study.
    Mol Psychiatry. 2025;30:2831-2839.
    PubMed     Abstract available
    
    
    
71. LUYKX JJ, Corbeil O, Karkkainen O, Tanskanen A, et al
    Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.
    Mol Psychiatry. 2025 Jul 1. doi: 10.1038/s41380-025-03080.
    PubMed     Abstract available
    
    
    June 2025
72. SZESZKO PR, Kowalchyk M, Chu KW, Aladin S, et al
    Investigation of brain white matter and social cognition in schizophrenia and schizotypal personality disorder using neurite orientation dispersion and density imaging.
    Mol Psychiatry. 2025 Jun 7. doi: 10.1038/s41380-025-03074.
    PubMed     Abstract available
    
    
    
73. SUI YV, Bertisch H, Goff DC, Samsonov A, et al
    Quantitative magnetization transfer and g-ratio imaging of white matter myelin in early psychotic spectrum disorders.
    Mol Psychiatry. 2025;30:2739-2747.
    PubMed     Abstract available
    
    
    May 2025
74. VILLARIN JM, Kellendonk C
    An ace in the hole? Opportunities and limits of using mice to understand schizophrenia neurobiology.
    Mol Psychiatry. 2025 May 22. doi: 10.1038/s41380-025-03060.
    PubMed     Abstract available
    
    
    
75. BYUN AJS, Lane E, Langholm C, Flathers M, et al
    Towards clinical subtypes in schizophrenia: integrating cognitive, functional, and digital phenotyping assessments.
    Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03054.
    PubMed     Abstract available
    
    
    
76. SAINT-GEORGES Z, MacDonald J, Al-Khalili R, Hamati R, et al
    Cholinergic system in schizophrenia: A systematic review and meta-analysis.
    Mol Psychiatry. 2025 May 20. doi: 10.1038/s41380-025-03023.
    PubMed     Abstract available
    
    
    
77. HUA L, Zeng X, Zhang K, Zhao Z, et al
    Reduced glymphatic clearance in early psychosis.
    Mol Psychiatry. 2025 May 19. doi: 10.1038/s41380-025-03058.
    PubMed     Abstract available
    
    
    
78. BANERJEE A, Wang HY, Borgmann-Winter KE, MacDonald ML, et al
    Editorial Expression of Concern: Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia.
    Mol Psychiatry. 2025 May 13. doi: 10.1038/s41380-025-03050.
    PubMed    
    
    
    
79. FARHANGDOOST N, Liao C, Liu Y, Rochefort D, et al
    Transcriptomic and epigenomic consequences of heterozygous loss-of-function mutations in AKAP11, a shared risk gene for bipolar disorder and schizophrenia.
    Mol Psychiatry. 2025 May 2. doi: 10.1038/s41380-025-03040.
    PubMed     Abstract available
    
    
    
80. HATANO M, Nakajima W, Tani H, Uchida H, et al
    Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography.
    Mol Psychiatry. 2025;30:1780-1790.
    PubMed     Abstract available
    
    
    April 2025
81. WANG HY, MacDonald ML, Borgmann-Winter KE, Banerjee A, et al
    Retraction Note: mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia.
    Mol Psychiatry. 2025 Apr 17. doi: 10.1038/s41380-025-02986.
    PubMed    
    
    
    
82. HATZIPANAYIOTI A, Walther S, Gangl N, Conring F, et al
    Aberrant personal space is associated with paranoia, altered stress regulation, and unfavourable outcomes at 6 months' follow-up in schizophrenia.
    Mol Psychiatry. 2025 Apr 9. doi: 10.1038/s41380-025-02999.
    PubMed     Abstract available
    
    
    
83. NUCIFORA LG, Ishizuka K, El Demerdash N, Lee BJ, et al
    Protein aggregation identified in olfactory neuronal cells is associated with cognitive impairments in a subset of living schizophrenia patients.
    Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02956.
    PubMed     Abstract available
    
    
    
84. XIE Y, Fu J, Liu L, Wang X, et al
    Genetic and neural mechanisms shared by schizophrenia and depression.
    Mol Psychiatry. 2025 Apr 3. doi: 10.1038/s41380-025-02975.
    PubMed     Abstract available
    
    
    
85. YAO S, Kendrick KM
    How does oxytocin modulate human behavior?
    Mol Psychiatry. 2025;30:1639-1651.
    PubMed     Abstract available
    
    
    
86. MIURA K, Yoshida M, Morita K, Fujimoto M, et al
    Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals.
    Mol Psychiatry. 2025;30:1594-1600.
    PubMed     Abstract available
    
    
    
87. ITAHASHI T, Yamashita A, Takahara Y, Yahata N, et al
    Generalizable and transportable resting-state neural signatures characterized by functional networks, neurotransmitters, and clinical symptoms in autism.
    Mol Psychiatry. 2025;30:1466-1478.
    PubMed     Abstract available
    
    
    March 2025
88. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
    Correction: Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
    Mol Psychiatry. 2025 Mar 31. doi: 10.1038/s41380-025-02987.
    PubMed    
    
    
    
89. RABALLO A, Poletti M, Preti A
    Increasing conceptual clarity and confounders identification: a pragmatic way to enhance prognostic precision in ENIGMA clinical high risk for psychosis (CHR-P).
    Mol Psychiatry. 2025 Mar 17. doi: 10.1038/s41380-025-02948.
    PubMed    
    
    
    
90. FENG YA, Chen WJ, Lin MC, Hsu JS, et al
    Paternal age, de novo mutation, and age at onset among co-affected schizophrenia sib-pairs: whole-genome sequencing in multiplex families.
    Mol Psychiatry. 2025 Mar 5. doi: 10.1038/s41380-025-02942.
    PubMed     Abstract available
    
    
    
91. ZHAO Q, Wei X, Yu W, Li X, et al
    Morphological alterations of the thymus gland in individuals with schizophrenia.
    Mol Psychiatry. 2025 Mar 4. doi: 10.1038/s41380-025-02946.
    PubMed     Abstract available
    
    
    
92. ARBABI K, Newton DF, Oh H, Davie MC, et al
    Transcriptomic pathology of neocortical microcircuit cell types across psychiatric disorders.
    Mol Psychiatry. 2025;30:1057-1068.
    PubMed     Abstract available
    
    
    
93. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    The number of episodes of major psychiatric and substance use disorders as an index of genetic risk and genetic heterogeneity.
    Mol Psychiatry. 2025;30:968-975.
    PubMed     Abstract available
    
    
    February 2025
94. GIACOMEL A, Martins D, Nordio G, Easmin R, et al
    Investigating dopaminergic abnormalities in schizophrenia and first-episode psychosis with normative modelling and multisite molecular neuroimaging.
    Mol Psychiatry. 2025 Feb 28. doi: 10.1038/s41380-025-02938.
    PubMed     Abstract available
    
    
    
95. KEIHANI A, Donati FL, Janssen SA, Huston CA, et al
    Multimodal evidence of mediodorsal thalamus-prefrontal circuit dysfunctions in clinical high-risk for psychosis: findings from a combined 7T fMRI, MRSI and sleep Hd-EEG study.
    Mol Psychiatry. 2025 Feb 15. doi: 10.1038/s41380-025-02924.
    PubMed     Abstract available
    
    
    
96. MINICHINO A, Davies C, Karpenko O, Christodoulou N, et al
    Preventing psychosis in people at clinical high risk: an updated meta-analysis by the World Psychiatric Association Preventive Psychiatry section.
    Mol Psychiatry. 2025 Feb 14. doi: 10.1038/s41380-025-02902.
    PubMed     Abstract available
    
    
    
97. DI RE J, Marini M, Hussain SI, Singh AK, et al
    betaIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia.
    Mol Psychiatry. 2025 Feb 7. doi: 10.1038/s41380-025-02917.
    PubMed     Abstract available
    
    
    
98. VINKE LN, Avanaki M, Jeffrey C, Harikumar A, et al
    Neural correlates of personal space regulation in psychosis: role of the inferior parietal cortex.
    Mol Psychiatry. 2025 Feb 3. doi: 10.1038/s41380-025-02906.
    PubMed     Abstract available
    
    
    January 2025
99. CHESTNYKH D, Muhle C, Schumacher F, Kalinichenko LS, et al
    Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
    Mol Psychiatry. 2025 Jan 17. doi: 10.1038/s41380-025-02893.
    PubMed     Abstract available
    
    
    
100. MARQUES D, Vaziri N, Greenway SC, Bousman C, et al
     DNA methylation and histone modifications associated with antipsychotic treatment: a systematic review.
     Mol Psychiatry. 2025;30:296-309.
     PubMed     Abstract available
     
     
     
101. CIULKINYTE A, Mountford HS, Fontanillas P, Bates TC, et al
     Genetic neurodevelopmental clustering and dyslexia.
     Mol Psychiatry. 2025;30:140-150.
     PubMed     Abstract available
     
     
     
102. LI X, Xue C, Zhu Z, Yu X, et al
     Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.
     Mol Psychiatry. 2025;30:111-121.
     PubMed     Abstract available
     
     
     December 2024
103. EISENBERG DP, Blackman RK, Tietcheu MG, Kohn PD, et al
     Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D(2/3) receptor availability in healthy individuals.
     Mol Psychiatry. 2024 Dec 27. doi: 10.1038/s41380-024-02873.
     PubMed     Abstract available
     
     
     
104. XIA C, Alliey-Rodriguez N, Tamminga CA, Keshavan MS, et al
     Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations.
     Mol Psychiatry. 2024 Dec 21. doi: 10.1038/s41380-024-02876.
     PubMed     Abstract available
     
     
     
105. SOLMI M, Fornaro M, Caiolo S, Lussignoli M, et al
     Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
     Mol Psychiatry. 2024 Dec 18. doi: 10.1038/s41380-024-02733.
     PubMed     Abstract available
     
     
     
106. COHEN LS, Arakelian M, Church TR, Dunk MM, et al
     The phenomenology of postpartum psychosis: preliminary findings from the Massachusetts General Hospital Postpartum Psychosis Project.
     Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02856.
     PubMed     Abstract available
     
     
     
107. BERNSTEIN HG, Nussbaumer M, Vasilevska V, Dobrowolny H, et al
     Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.
     Mol Psychiatry. 2024 Dec 5. doi: 10.1038/s41380-024-02861.
     PubMed     Abstract available
     
     
     
108. SCHALBROECK R, van Hooijdonk CFM, Bos DPA, Booij J, et al
     Chronic social stressors and striatal dopamine functioning in humans: A systematic review of SPECT and PET studies.
     Mol Psychiatry. 2024;29:3841-3856.
     PubMed     Abstract available
     
     
     November 2024
109. SABE M, Sulstarova A, Glangetas A, De Pieri M, et al
     Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
     Mol Psychiatry. 2024 Nov 27. doi: 10.1038/s41380-024-02800.
     PubMed     Abstract available
     
     
     
110. NELSON EA, Kraguljac NV, Bashir A, Cofield SS, et al
     A longitudinal study of hippocampal subfield volumes and hippocampal glutamate levels in antipsychotic-naive first episode psychosis patients.
     Mol Psychiatry. 2024 Nov 23. doi: 10.1038/s41380-024-02812.
     PubMed     Abstract available
     
     
     
111. WEIDENAUER A, Dajic I, Praschak-Rieder N, Willeit M, et al
     The dopaminergic basis of negative symptoms in schizophrenia: an addendum.
     Mol Psychiatry. 2024 Nov 20. doi: 10.1038/s41380-024-02828.
     PubMed    
     
     
     
112. CHEN L, Huai C, Song C, Wu S, et al
     Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction.
     Mol Psychiatry. 2024 Nov 19. doi: 10.1038/s41380-024-02841.
     PubMed     Abstract available
     
     
     
113. WALKER A, Karlsson R, Szatkiewicz JP, Thornton LM, et al
     Genome-wide copy number variation association study in anorexia nervosa.
     Mol Psychiatry. 2024 Nov 12. doi: 10.1038/s41380-024-02811.
     PubMed     Abstract available
     
     
     
114. NISHA AJI K, Lalang N, Ramos-Jimenez C, Rahimian R, et al
     Evidence of altered monoamine oxidase B, an astroglia marker, in early psychosis and high-risk state.
     Mol Psychiatry. 2024 Nov 7. doi: 10.1038/s41380-024-02816.
     PubMed     Abstract available
     
     
     
115. SOCRATES AJ, Mullins N, Gur RC, Gur RE, et al
     Polygenic risk of social isolation behavior and its influence on psychopathology and personality.
     Mol Psychiatry. 2024;29:3599-3606.
     PubMed     Abstract available
     
     
     
116. LUO J, Li L, Niu M, Kong D, et al
     Genetic regulation of human brain proteome reveals proteins implicated in psychiatric disorders.
     Mol Psychiatry. 2024;29:3330-3343.
     PubMed     Abstract available
     
     
     October 2024
117. LEE H, Lee JH, Lee S, Lim JS, et al
     Comorbid health outcomes in patients with schizophrenia: an umbrella review of systematic reviews and meta-analyses.
     Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02792.
     PubMed     Abstract available
     
     
     
118. DEVINE EA, Imami AS, Eby H, Sahay S, et al
     Neuronal alterations in AKT isotype expression in schizophrenia.
     Mol Psychiatry. 2024 Oct 18. doi: 10.1038/s41380-024-02770.
     PubMed     Abstract available
     
     
     
119. SCOTT DS, Subramanian M, Yamamoto J, Tamminga CA, et al
     Schizophrenia pathology reverse-translated into mouse shows hippocampal hyperactivity, psychosis behaviors and hyper-synchronous events.
     Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02781.
     PubMed     Abstract available
     
     
     
120. DEMPSTER EL, Wong CCY, Burrage J, Hannon E, et al
     Methylomic signature of current cannabis use in two first-episode psychosis cohorts.
     Mol Psychiatry. 2024 Oct 16. doi: 10.1038/s41380-024-02689.
     PubMed     Abstract available
     
     
     
121. KEANE BP, Abrham YT, Cole MW, Johnson BA, et al
     Functional dysconnectivity of visual and somatomotor networks yields a simple and robust biomarker for psychosis.
     Mol Psychiatry. 2024 Oct 4. doi: 10.1038/s41380-024-02767.
     PubMed     Abstract available
     
     
     
122. LIUFU C, Luo L, Pang T, Zheng H, et al
     Integration of multi-omics summary data reveals the role of N6-methyladenosine in neuropsychiatric disorders.
     Mol Psychiatry. 2024;29:3141-3150.
     PubMed     Abstract available
     
     
     September 2024
123. CHOE E, Kim M, Choi S, Oh H, et al
     MRI textural plasticity in limbic gray matter associated with clinical response to electroconvulsive therapy for psychosis.
     Mol Psychiatry. 2024 Sep 26. doi: 10.1038/s41380-024-02755.
     PubMed     Abstract available
     
     
     
124. SAPIENZA J, Martini F, Comai S, Cavallaro R, et al
     Psychedelics and schizophrenia: a double-edged sword.
     Mol Psychiatry. 2024 Sep 18. doi: 10.1038/s41380-024-02743.
     PubMed     Abstract available
     
     
     
125. KILTSCHEWSKIJ DJ, Reay WR, Cairns MJ
     Schizophrenia is associated with altered DNA methylation variance.
     Mol Psychiatry. 2024 Sep 13. doi: 10.1038/s41380-024-02749.
     PubMed     Abstract available
     
     
     
126. GARCIA-SAN-MARTIN N, Bethlehem RAI, Mihalik A, Seidlitz J, et al
     Molecular and micro-architectural mapping of gray matter alterations in psychosis.
     Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724.
     PubMed     Abstract available
     
     
     
127. NANI JV, Muotri AR, Hayashi MAF
     Peering into the mind: unraveling schizophrenia's secrets using models.
     Mol Psychiatry. 2024 Sep 8. doi: 10.1038/s41380-024-02728.
     PubMed     Abstract available
     
     
     
128. ROMANOVSKY E, Choudhary A, Peles D, Abu-Akel A, et al
     Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons.
     Mol Psychiatry. 2024 Sep 5. doi: 10.1038/s41380-024-02740.
     PubMed     Abstract available
     
     
     
129. PHADKE RA, Brack A, Fournier LA, Kruzich E, et al
     The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking.
     Mol Psychiatry. 2024 Sep 3. doi: 10.1038/s41380-024-02701.
     PubMed     Abstract available
     
     
     
130. CHAN JKN, Lee KCK, Correll CU, So YK, et al
     Adverse obstetric and neonatal outcomes associated with maternal schizophrenia-spectrum disorders and prenatal antipsychotic use: a meta-analysis of 37,214,330 pregnancy deliveries and propensity-score weighted population-based cohort study assessing
     Mol Psychiatry. 2024 Sep 2. doi: 10.1038/s41380-024-02723.
     PubMed     Abstract available
     
     
     
131. CROUSE JJ, Park SH, Byrne EM, Mitchell BL, et al
     Patterns of stressful life events and polygenic scores for five mental disorders and neuroticism among adults with depression.
     Mol Psychiatry. 2024;29:2765-2773.
     PubMed     Abstract available
     
     
     
132. GAITONDE SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, et al
     Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor.
     Mol Psychiatry. 2024;29:2753-2764.
     PubMed     Abstract available
     
     
     
133. KAMPE A, Suvisaari J, Lahteenvuo M, Singh T, et al
     Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders.
     Mol Psychiatry. 2024;29:2733-2741.
     PubMed     Abstract available
     
     
     
134. GERACI F, Passiatore R, Penzel N, Laudani S, et al
     Sex dimorphism controls dysbindin-related cognitive dysfunctions in mice and humans with the contribution of COMT.
     Mol Psychiatry. 2024;29:2666-2677.
     PubMed     Abstract available
     
     
     August 2024
135. KAMBALI M, Li Y, Unichenko P, Feria Pliego JA, et al
     An increased copy number of glycine decarboxylase (GLDC) associated with psychosis reduces extracellular glycine and impairs NMDA receptor function.
     Mol Psychiatry. 2024 Aug 30. doi: 10.1038/s41380-024-02711.
     PubMed     Abstract available
     
     
     
136. AYMERICH C, Salazar de Pablo G, Pacho M, Perez-Rodriguez V, et al
     All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.
     Mol Psychiatry. 2024 Aug 22. doi: 10.1038/s41380-024-02694.
     PubMed     Abstract available
     
     
     
137. LI Z, Mukherjee D, Duric B, Austin-Zimmerman I, et al
     Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents.
     Mol Psychiatry. 2024 Aug 2. doi: 10.1038/s41380-024-02668.
     PubMed     Abstract available
     
     
     
138. ALLOTT K, Chopra S, Rogers J, Dauvermann MR, et al
     Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action.
     Mol Psychiatry. 2024;29:2571-2574.
     PubMed    
     
     
     July 2024
139. FORNARO M, Caiazza C, Billeci M, Berk M, et al
     Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis "Nutra NMA SCZ".
     Mol Psychiatry. 2024 Jul 18. doi: 10.1038/s41380-024-02645.
     PubMed     Abstract available
     
     
     
140. ARANDA S, Jimenez E, Canales-Rodriguez EJ, Verdolini N, et al
     Processing speed mediates the relationship between DDR1 and psychosocial functioning in euthymic patients with bipolar disorder presenting psychotic symptoms.
     Mol Psychiatry. 2024;29:2050-2058.
     PubMed     Abstract available
     
     
     June 2024
141. CAMPORESI S, Xin L, Golay P, Eap CB, et al
     Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.
     Mol Psychiatry. 2024 Jun 7. doi: 10.1038/s41380-024-02631.
     PubMed     Abstract available
     
     
     
142. MARTINO M, Magioncalda P
     A working model of neural activity and phenomenal experience in psychosis.
     Mol Psychiatry. 2024 Jun 6. doi: 10.1038/s41380-024-02607.
     PubMed     Abstract available
     
     
     
143. CHO KIK, Zhang F, Penzel N, Seitz-Holland J, et al
     Excessive interstitial free-water in cortical gray matter preceding accelerated volume changes in individuals at clinical high risk for psychosis.
     Mol Psychiatry. 2024 Jun 3. doi: 10.1038/s41380-024-02597.
     PubMed     Abstract available
     
     
     
144. LIAO Y, Yu H, Zhang Y, Lu Z, et al
     Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.
     Mol Psychiatry. 2024;29:1857-1868.
     PubMed     Abstract available
     
     
     May 2024
145. STERN S, Zhang L, Wang M, Wright R, et al
     Monozygotic twins discordant for schizophrenia differ in maturation and synaptic transmission.
     Mol Psychiatry. 2024 May 4. doi: 10.1038/s41380-024-02561.
     PubMed     Abstract available
     
     
     
146. HILL MD, Gill SS, Le-Niculescu H, MacKie O, et al
     Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics.
     Mol Psychiatry. 2024;29:1528-1549.
     PubMed     Abstract available
     
     
     
147. YANG K, Hasegawa Y, Bhattarai JP, Hua J, et al
     Inflammation-related pathology in the olfactory epithelium: its impact on the olfactory system in psychotic disorders.
     Mol Psychiatry. 2024;29:1453-1464.
     PubMed     Abstract available
     
     
     April 2024
148. SPATHOPOULOU A, Sauerwein GA, Marteau V, Podlesnic M, et al
     Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia.
     Mol Psychiatry. 2024 Apr 29. doi: 10.1038/s41380-024-02568.
     PubMed     Abstract available
     
     
     
149. SHARKEY RJ, Bacon C, Peterson Z, Rootes-Murdy K, et al
     Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset.
     Mol Psychiatry. 2024 Apr 26. doi: 10.1038/s41380-024-02563.
     PubMed     Abstract available
     
     
     
150. SUPEKAR K, de Los Angeles C, Ryali S, Kushan L, et al
     Robust and replicable functional brain signatures of 22q11.2 deletion syndrome and associated psychosis: a deep neural network-based multi-cohort study.
     Mol Psychiatry. 2024 Apr 12. doi: 10.1038/s41380-024-02495.
     PubMed     Abstract available
     
     
     
151. TOTZEK JF, Chakravarty MM, Joober R, Malla A, et al
     Longitudinal inference of multiscale markers in psychosis: from hippocampal centrality to functional outcome.
     Mol Psychiatry. 2024 Apr 11. doi: 10.1038/s41380-024-02549.
     PubMed     Abstract available
     
     
     
152. OKADA N, Yahata N, Koshiyama D, Morita K, et al
     Longitudinal trajectories of anterior cingulate glutamate and subclinical psychotic experiences in early adolescence: the impact of bullying victimization.
     Mol Psychiatry. 2024;29:939-950.
     PubMed     Abstract available
     
     
     March 2024
153. CHEN S, Tan Y, Tian L
     Immunophenotypes in psychosis: is it a premature inflamm-aging disorder?
     Mol Psychiatry. 2024 Mar 26. doi: 10.1038/s41380-024-02539.
     PubMed     Abstract available
     
     
     
154. KOSKUVI M, Porsti E, Hewitt T, Rasanen N, et al
     Genetic contribution to microglial activation in schizophrenia.
     Mol Psychiatry. 2024 Mar 22. doi: 10.1038/s41380-024-02529.
     PubMed     Abstract available
     
     
     
155. TESFAYE M, Spindola LM, Stavrum AK, Shadrin A, et al
     Sex effects on DNA methylation affect discovery in epigenome-wide association study of schizophrenia.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02513.
     PubMed     Abstract available
     
     
     
156. FEOLA B, Beermann A, Manzanarez Felix K, Coleman M, et al
     Data-driven, connectome-wide analysis identifies psychosis-specific brain correlates of fear and anxiety.
     Mol Psychiatry. 2024 Mar 19. doi: 10.1038/s41380-024-02512.
     PubMed     Abstract available
     
     
     
157. BIGDELI TB, Barr PB, Rajeevan N, Graham DP, et al
     Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02472.
     PubMed     Abstract available
     
     
     
158. WARREN TL, Tubbs JD, Lesh TA, Corona MB, et al
     Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis.
     Mol Psychiatry. 2024 Mar 15. doi: 10.1038/s41380-024-02457.
     PubMed     Abstract available
     
     
     February 2024
159. FOUNTOULAKIS KN, Tsapakis EM
     Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders.
     Mol Psychiatry. 2024 Feb 19. doi: 10.1038/s41380-024-02458.
     PubMed    
     
     
     
160. SONG J, Jonsson L, Lu Y, Bergen SE, et al
     Key subphenotypes of bipolar disorder are differentially associated with polygenic liabilities for bipolar disorder, schizophrenia, and major depressive disorder.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02448.
     PubMed     Abstract available
     
     
     
161. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     Correction: On the proportion of patients who experience a prodrome prior to psychosis onset: a systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02481.
     PubMed    
     
     
     
162. KOTOV R, Carpenter WT, Cicero DC, Correll CU, et al
     Psychosis superspectrum II: neurobiology, treatment, and implications.
     Mol Psychiatry. 2024 Feb 14. doi: 10.1038/s41380-024-02410.
     PubMed     Abstract available
     
     
     
163. ZHU Y, Maikusa N, Radua J, Samann PG, et al
     Using brain structural neuroimaging measures to predict psychosis onset for individuals at clinical high-risk.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02426.
     PubMed     Abstract available
     
     
     
164. GEORGIADIS F, Lariviere S, Glahn D, Hong LE, et al
     Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study.
     Mol Psychiatry. 2024 Feb 9. doi: 10.1038/s41380-024-02442.
     PubMed     Abstract available
     
     
     
165. BENRIMOH D, Dlugunovych V, Wright AC, Phalen P, et al
     On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02415.
     PubMed     Abstract available
     
     
     
166. PODVIN S, Jones J, Kang A, Goodman R, et al
     Human iN neuronal model of schizophrenia displays dysregulation of chromogranin B and related neuropeptide transmitter signatures.
     Mol Psychiatry. 2024 Feb 2. doi: 10.1038/s41380-024-02422.
     PubMed     Abstract available
     
     
     
167. SHAKESHAFT A, Martin J, Dennison CA, Riglin L, et al
     Estimating the impact of transmitted and non-transmitted psychiatric and neurodevelopmental polygenic scores on youth emotional problems.
     Mol Psychiatry. 2024;29:238-246.
     PubMed     Abstract available
     
     
     January 2024
168. CHUNG Y, Dienel SJ, Belch MJ, Fish KN, et al
     Altered Rbfox1-Vamp1 pathway and prefrontal cortical dysfunction in schizophrenia.
     Mol Psychiatry. 2024 Jan 25. doi: 10.1038/s41380-024-02417.
     PubMed     Abstract available
     
     
     
169. CHEN H, Lei Y, Li R, Xia X, et al
     Resting-state EEG dynamic functional connectivity distinguishes non-psychotic major depression, psychotic major depression and schizophrenia.
     Mol Psychiatry. 2024 Jan 24. doi: 10.1038/s41380-023-02395.
     PubMed     Abstract available
     
     
     
170. DAVIES C, Martins D, Dipasquale O, McCutcheon RA, et al
     Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
     Mol Psychiatry. 2024 Jan 19. doi: 10.1038/s41380-024-02406.
     PubMed     Abstract available
     
     
     
171. WOLFF A, Northoff G
     Temporal imprecision of phase coherence in schizophrenia and psychosis-dynamic mechanisms and diagnostic marker.
     Mol Psychiatry. 2024 Jan 16. doi: 10.1038/s41380-023-02337.
     PubMed     Abstract available
     
     
     
172. JONAS KG, Cannon TD, Docherty AR, Dwyer D, et al
     Psychosis superspectrum I: Nosology, etiology, and lifespan development.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02388.
     PubMed     Abstract available
     
     
     
173. SI S, Bi A, Yu Z, See C, et al
     Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study.
     Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02343.
     PubMed     Abstract available
     
     
     
174. RUBIO JM, Lencz T, Cao H, Kraguljac N, et al
     Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.
     Mol Psychiatry. 2024 Jan 4. doi: 10.1038/s41380-023-02381.
     PubMed     Abstract available
     
     
     December 2023
175. DONG P, Voloudakis G, Fullard JF, Hoffman GE, et al
     Convergence of the dysregulated regulome in schizophrenia with polygenic risk and evolutionarily constrained enhancers.
     Mol Psychiatry. 2023 Dec 25. doi: 10.1038/s41380-023-02370.
     PubMed     Abstract available
     
     
     
176. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia.
     Mol Psychiatry. 2023 Dec 20. doi: 10.1038/s41380-023-02365.
     PubMed     Abstract available
     
     
     
177. KOMATSU H, Onoguchi G, Silverstein SM, Jerotic S, et al
     Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.
     Mol Psychiatry. 2023 Dec 11. doi: 10.1038/s41380-023-02340.
     PubMed     Abstract available
     
     
     
178. OKADA N, Fukunaga M, Miura K, Nemoto K, et al
     Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification.
     Mol Psychiatry. 2023;28:5206-5216.
     PubMed     Abstract available
     
     
     
179. GRIECO SF, Johnston KG, Gao P, Garduno BM, et al
     Anatomical and molecular characterization of parvalbumin-cholecystokinin co-expressing inhibitory interneurons: implications for neuropsychiatric conditions.
     Mol Psychiatry. 2023;28:5293-5308.
     PubMed     Abstract available
     
     
     
180. WEI W, Deng L, Qiao C, Yin Y, et al
     Neural variability in three major psychiatric disorders.
     Mol Psychiatry. 2023;28:5217-5227.
     PubMed     Abstract available
     
     
     
181. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
     Selecting cases of major psychiatric and substance use disorders in Swedish national registries on the basis of clinical features to maximize the strength or specificity of the genetic risk.
     Mol Psychiatry. 2023;28:5195-5205.
     PubMed     Abstract available
     
     
     
182. ZHENG H, Webster MJ, Weickert CS, Beasley CL, et al
     Cytomegalovirus antibodies are associated with mood disorders, suicide, markers of neuroinflammation, and microglia activation in postmortem brain samples.
     Mol Psychiatry. 2023;28:5282-5292.
     PubMed     Abstract available
     
     
     November 2023
183. NORTHOFF G, Daub J, Hirjak D
     Overcoming the translational crisis of contemporary psychiatry - converging phenomenological and spatiotemporal psychopathology.
     Mol Psychiatry. 2023;28:4492-4499.
     PubMed     Abstract available
     
     
     October 2023
184. OWEN MJ, Legge SE, Rees E, Walters JTR, et al
     Genomic findings in schizophrenia and their implications.
     Mol Psychiatry. 2023 Oct 18. doi: 10.1038/s41380-023-02293.
     PubMed     Abstract available
     
     
     
185. LESH TA, Iosif AM, Tanase C, Vlasova RM, et al
     Extracellular free water elevations are associated with brain volume and maternal cytokine response in a longitudinal nonhuman primate maternal immune activation model.
     Mol Psychiatry. 2023;28:4185-4194.
     PubMed     Abstract available
     
     
     
186. ARNATKEVICIUTE A, Lemire M, Morrison C, Mooney M, et al
     Trans-ancestry meta-analysis of genome wide association studies of inhibitory control.
     Mol Psychiatry. 2023;28:4175-4184.
     PubMed     Abstract available
     
     
     
187. RAVEN EP, Veraart J, Kievit RA, Genc S, et al
     In vivo evidence of microstructural hypo-connectivity of brain white matter in 22q11.2 deletion syndrome.
     Mol Psychiatry. 2023;28:4342-4352.
     PubMed     Abstract available
     
     
     September 2023
188. ODKHUU S, Kim WS, Tsogt U, Shen J, et al
     Network biomarkers in recovered psychosis patients who discontinued antipsychotics.
     Mol Psychiatry. 2023 Sep 29. doi: 10.1038/s41380-023-02279.
     PubMed     Abstract available
     
     
     
189. HARRISON PJ, Bannerman DM
     GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.
     Mol Psychiatry. 2023 Sep 22. doi: 10.1038/s41380-023-02265.
     PubMed     Abstract available
     
     
     
190. ZHOU J, Xia Y, Li M, Chen Y, et al
     A higher dysregulation burden of brain DNA methylation in female patients implicated in the sex bias of Schizophrenia.
     Mol Psychiatry. 2023 Sep 11. doi: 10.1038/s41380-023-02243.
     PubMed     Abstract available
     
     
     
191. FLYNN LT, Gao WJ
     DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness.
     Mol Psychiatry. 2023 Sep 7. doi: 10.1038/s41380-023-02235.
     PubMed     Abstract available
     
     
     
192. SOLMI M, Cortese S, Vita G, De Prisco M, et al
     An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders.
     Mol Psychiatry. 2023;28:3671-3687.
     PubMed     Abstract available
     
     
     
193. MERRITT K, Luque Laguna P, Sethi A, Drakesmith M, et al
     The impact of cumulative obstetric complications and childhood trauma on brain volume in young people with psychotic experiences.
     Mol Psychiatry. 2023;28:3688-3697.
     PubMed     Abstract available
     
     
     
194. WOOTTON O, Shadrin AA, Mohn C, Susser E, et al
     Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability.
     Mol Psychiatry. 2023;28:4011-4019.
     PubMed     Abstract available
     
     
     
195. CAMPBELL PD, Lee I, Thyme S, Granato M, et al
     Mitochondrial proteins encoded by the 22q11.2 neurodevelopmental locus regulate neural stem and progenitor cell proliferation.
     Mol Psychiatry. 2023;28:3769-3781.
     PubMed     Abstract available
     
     
     August 2023
196. NURMI EL, Laughlin CP, de Wit H, Palmer AA, et al
     Polygenic contributions to performance on the Balloon Analogue Risk Task.
     Mol Psychiatry. 2023;28:3524-3530.
     PubMed     Abstract available
     
     
     
197. HETTEMA JM, van den Oord EJCG, Zhao M, Xie LY, et al
     Methylome-wide association study of anxiety disorders.
     Mol Psychiatry. 2023;28:3484-3492.
     PubMed     Abstract available
     
     
     May 2023
198. LICINIO J, Wong ML
     Psychosis and autism spectrum disorder: a special issue of Molecular Psychiatry.
     Mol Psychiatry. 2023;28:1830-1832.
     PubMed    
     
     
     
199. VAN DEN OORD EJCG, Xie LY, Zhao M, Campbell TL, et al
     Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples.
     Mol Psychiatry. 2023;28:2088-2094.
     PubMed     Abstract available
     
     
     
200. MAYELI A, LaGoy AD, Smagula SF, Wilson JD, et al
     Shared and distinct abnormalities in sleep-wake patterns and their relationship with the negative symptoms of Schizophrenia Spectrum Disorder patients.
     Mol Psychiatry. 2023;28:2049-2057.
     PubMed     Abstract available
     
     
     
201. FOND G, Vidal M, Joseph M, Etchecopar-Etchart D, et al
     Self-stigma in schizophrenia: a systematic review and meta-analysis of 37 studies from 25 high- and low-to-middle income countries.
     Mol Psychiatry. 2023;28:1920-1931.
     PubMed     Abstract available
     
     
     
202. LU C, Zhu X, Feng Y, Ao W, et al
     Atypical antipsychotics antagonize GABA(A) receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors.
     Mol Psychiatry. 2023;28:2107-2121.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum